[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Isothermal Nucleic Acid Amplification Technology/INAAT Market by Product (Assay & Kit, System), Application (Infectious disease [HIV, Influenza], Blood Screening), Type (LAMP, SDA, NASBA, HDA), End User, Region - Global Forecast to 2024

January 2020 | 152 pages | ID: I03690FDF14EN
MarketsandMarkets

US$ 5,650.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
“The rising prevalence of infectious diseases and the introduction of newer pathogens, and the cost-benefits of INAAT is expected to drive the overall growth of the INAAT market”

The global isothermal nucleic acid amplification technology (INAAT) market size is expected to grow from USD 1.9 billion in 2019 to USD 3.3 billion by 2024, at a CAGR of 11.0% during the forecast period. The major factors driving the growth of this market include the rising prevalence of infectious diseases and the introduction of newer pathogens, the need for prompt diagnosis, the increasing number of blood transfusions and donations, and the cost-benefits of INAAT. However, the extensive usage and reliance on PCR are expected to limit the adoption of INAAT.

“Assay, kits and reagents segment is expected to grow at the highest CAGR during the forecast period”

Based on the product, the market is segmented broadly into assay, kits, and reagents, and systems. The assay, kits, and reagents segment is projected to grow at the highest CAGR during the forecast period. The increasing number of infectious disease diagnostic tests carried out; the rising prevalence of infectious diseases; the continuous launch of newer, faster, and more reliable POC products; increasing approvals of CLIA-waived tests; accessibility to a wide range of reagents; repeated purchase of reagents; and the increasing use of reagents in therapeutics, basic research, and assay development.

“TMA is expected to grow at CAGR during the forecast period”

Based on type, the INAAT market is segmented into TMA, LAMP, SDA, HDA, NASBA, and other INAAT technologies. The TMA segment is expected to be the fastest-growing segment during the forecast period due to the growing reliance on POC diagnosis in hospitals and blood banks.

“Infectious disease diagnosis segment to grow at the highest CAGR during the forecast period.”

The INAAT market, by the applications, has been categorized into infectious disease diagnosis, blood screening, and other applications (cancer diagnosis, cancer research, and laboratory research, which encompass cDNA preparation, whole-genome amplification (WGA), single-nucleotide polymorphism (SNP), and mutation analysis). Infectious disease diagnosis segment to grow at the highest CAGR during the forecast period owing to the increasing number of infectious disease diagnostic tests carried out and rising prevalence of infectious diseases, among others.

“Asia Pacific region to account for the largest share of the global INAAT market in 2019.”

Asia Pacific is expected to be the fastest-growing segment during the forecast period. Factors such as the sustained economic growth in several Asia Pacific countries, the rising disposable income, healthcare infrastructure modernization, increasing penetration of cutting-edge diagnostic technologies (including INAAT) for research and clinical applications, high infectious disease burden, availability of low-cost POC INAAT assays, and growing awareness among physicians and healthcare professionals about the benefits of gene-based disease diagnosis and treatment in Asia Pacific countries are expected to support market growth in this region during the forecast period.

In-depth interviews were conducted with Chief Executive Officers (CEOs), marketing directors, other innovation and technology directors, and executives from various key organizations operating in the INAAT market.
  • By Respondent Type: Supply Side: 80%, Demand Side: 20%
  • By Designation: C-level Executives: 25%, Directors: 18%, and Others: 57%
  • By Region: North America: 50%, Europe: 20%, APAC: 20%, and RoW: 10%
The INAAT market comprises major players such as Grifols S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories, Inc. (US), Becton, Dickinson & Company (US), and Meridian Bioscience (US). The study includes an in-depth competitive analysis of these key players in the INAAT market, along with their company profiles, recent developments, and key market strategies.

Research Coverage:

The study covers the INAAT market across various segments. It aims at estimating the market size and the growth potential of this market across different segments based on the product, type, application, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall INAAT market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, and opportunities
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
  1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
  1.3.1 MARKETS COVERED
  1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
  2.1.1 SECONDARY DATA
    2.1.1.1 Secondary sources
  2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
  2.2.1 DISEASE-BASED MARKET ESTIMATION APPROACH
  2.2.2 MNM-KNOW APPROACH
  2.2.3 APPLICATION-BASED MARKET ESTIMATION APPROACH
  2.2.4 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET OVERVIEW
4.2 NORTH AMERICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET SHARE, BY PRODUCT & COUNTRY (2019)
4.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY END USER
4.4 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY APPLICATION
4.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY TYPE

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
  5.2.1 DRIVERS
    5.2.1.1 Rising prevalence of infectious diseases and the emergence of
newer pathogens
    5.2.1.2 Need for prompt diagnosis and rapid treatment
    5.2.1.3 Increasing number of blood transfusions and donations
    5.2.1.4 Cost-benefits of INAAT
  5.2.2 RESTRAINTS
    5.2.2.1 Dominance of PCR
  5.2.3 OPPORTUNITIES
    5.2.3.1 Technology optimization and development
    5.2.3.2 Emerging economies

6 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT

6.1 INTRODUCTION
6.2 ASSAYS, KITS, AND REAGENTS
  6.2.1 ASSAYS, KITS, & REAGENTS ACCOUNTED FOR THE LARGEST SHARE OF
THE MARKET IN 2018
6.3 SYSTEMS
  6.3.1 MARKET FOR SYSTEMS TO WITNESS STEADY GROWTH DUE TO MODERATE REQUIREMENT IN HOSPITALS AND CLINICAL LABORATORIES

7 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY TYPE

7.1 INTRODUCTION
7.2 TRANSCRIPTION-MEDIATED AMPLIFICATION
  7.2.1 TMA ACCOUNTS FOR THE LARGEST SHARE OF THE MARKET
7.3 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION
  7.3.1 SPEED, STABILITY, AND SENSITIVITY HAVE DRIVEN THE USE OF LAMP
7.4 STRAND DISPLACEMENT AMPLIFICATION
  7.4.1 MIRNA AMPLIFICATION FOR CANCER DIAGNOSIS IS THE MAJOR APPLICATION OF SDA
7.5 HELICASE-DEPENDENT AMPLIFICATION
  7.5.1 COMPATIBILITY WITH MICROFLUIDIC TECHNOLOGIES & DEVELOPMENT OF LAB-ON-CHIP DEVICES TO SUPPORT MARKET GROWTH
7.6 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION
  7.6.1 ADVANTAGES OF NASBA OVER PCR HAVE ENHANCED ITS ADOPTION IN CLINICAL SETTINGS
7.7 OTHER TECHNOLOGIES

8 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY APPLICATION

8.1 INTRODUCTION
8.2 INFECTIOUS DISEASE DIAGNOSIS
  8.2.1 HEPATITIS
    8.2.1.1 Need to combat the high prevalence of hepatitis has raised
the demand for INAAT assays
  8.2.2 CT/NG
    8.2.2.1 Adoption of INAAT for CT/NG diagnosis is growing owing to its advantages over traditional diagnostic techniques
  8.2.3 HIV
    8.2.3.1 New product development will provide considerable potential for growth in the near future
  8.2.4 INFLUENZA
    8.2.4.1 NASBA, LAMP, and SAMBA are considered highly efficient and reliable methods of influenza diagnosis
  8.2.5 OTHER INFECTIOUS DISEASES
8.3 BLOOD SCREENING
  8.3.1 INCREASING NUMBER OF BLOOD DONATIONS AND TRANSFUSIONS HAVE DRIVEN THE USE OF INAAT IN BLOOD SCREENING APPLICATIONS
8.4 OTHER APPLICATIONS

9 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY END USER

9.1 INTRODUCTION
9.2 HOSPITALS
  9.2.1 HOSPITALS FORMED THE LARGEST END-USER SEGMENT IN THE INAAT MARKET IN 2018
9.3 REFERENCE LABORATORIES
  9.3.1 OUTSOURCING OF TESTS FROM SMALL HOSPITALS, PHYSICIANS’ OFFICES, AND CLINICS TO SUPPORT THE GROWTH OF THIS END-USER SEGMENT
9.4 ACADEMIC & RESEARCH INSTITUTES
  9.4.1 INDUSTRY-ACADEMIA COLLABORATIONS SUPPORTING THE ADOPTION
OF INAAT
9.5 OTHER END USERS

10 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY REGION

10.1 INTRODUCTION
10.2 NORTH AMERICA
  10.2.1 US
    10.2.1.1 US is a well-developed market for genome analysis techniques
  10.2.2 CANADA
    10.2.2.1 Investments for genomic research and development of diagnostics are supporting market growth in Canada
10.3 EUROPE
  10.3.1 GERMANY
    10.3.1.1 Germany dominated the European INAAT market in 2018
  10.3.2 FRANCE
    10.3.2.1 Supportive government policies that aim to ease public access to diagnostic assay procedures to drive growth in the INAAT market
  10.3.3 UK
    10.3.3.1 Adoption of INAAT products is expected to increase in the UK as a result of the growing focus of public and private organizations on genomics research
  10.3.4 REST OF EUROPE
10.4 ASIA PACIFIC
  10.4.1 ASIA PACIFIC TO OFFER SIGNIFICANT GROWTH OPPORTUNITIES FOR INAAT MARKET PLAYERS
10.5 REST OF THE WORLD
  10.5.1 THE ROW INAAT MARKET IS SIGNIFICANTLY SMALLER THAN OTHER MARKETS

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 MARKET RANKING ANALYSIS, 2018
11.3 COMPETITIVE LEADERSHIP MAPPING
  11.3.1 VISIONARY LEADERS
  11.3.2 INNOVATORS
  11.3.3 DYNAMIC DIFFERENTIATORS
  11.3.4 EMERGING COMPANIES
11.4 COMPETITIVE SCENARIO
  11.4.1 KEY PRODUCT LAUNCHES
  11.4.2 KEY ACQUISITIONS
  11.4.3 KEY PARTNERSHIPS, AGREEMENTS, CONTRACTS, AND COLLABORATIONS
  11.4.4 KEY EXPANSIONS

12 COMPANY PROFILES

(Business overview, Products offered, Recent developments, MNM view)*
12.1 GRIFOLS, S.A.
12.2 HOLOGIC, INC.
12.3 ABBOTT LABORATORIES, INC.
12.4 BECTON, DICKINSON AND COMPANY
12.5 MERIDIAN BIOSCIENCE
12.6 EIKEN CHEMICALS CO., LTD.
12.7 QUIDEL CORPORATION
12.8 TECAN TRADING AG
12.9 DIASORIN GROUP S.P.A
12.10 QIAGEN
12.11 ILLUMINA, INC.
12.12 THERMO FISHER SCIENTIFIC, INC.
12.13 BIOM?RIEUX SA
12.14 GE HEALTHCARE
12.15 OTHER COMPANIES
  12.15.1 NEW ENGLAND BIOLABS, INC.
  12.15.2 LUCIGEN CORPORATION
  12.15.3 USTAR BIOTECHNOLOGIES LTD.
  12.15.4 TWISTDX LIMITED
  12.15.5 MAST GROUP LTD.
  12.15.6 GENOMTEC SA
*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX

13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS

LIST OF TABLES

TABLE 1 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 2 INAAT ASSAYS, KITS, & REAGENTS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 3 NORTH AMERICA: INAAT ASSAYS, KITS, & REAGENTS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 4 EUROPE: INAAT ASSAYS, KITS, & REAGENTS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 5 INAAT SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 6 NORTH AMERICA: INAAT SYSTEMS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 7 EUROPE: INAAT SYSTEMS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 8 INAAT MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 9 INAAT MARKET FOR TMA, BY REGION, 2017–2024 (USD MILLION)
TABLE 10 NORTH AMERICA: INAAT MARKET FOR TMA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 11 EUROPE: INAAT MARKET FOR TMA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 12 INAAT MARKET FOR LAMP, BY REGION, 2017–2024 (USD MILLION)
TABLE 13 NORTH AMERICA: INAAT MARKET FOR LAMP, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 14 EUROPE: INAAT MARKET FOR LAMP, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 15 INAAT MARKET FOR SDA, BY REGION, 2017–2024 (USD MILLION)
TABLE 16 NORTH AMERICA: INAAT MARKET FOR SDA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 17 EUROPE: INAAT MARKET FOR SDA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 18 INAAT MARKET FOR HDA, BY REGION, 2017–2024 (USD MILLION)
TABLE 19 NORTH AMERICA: INAAT MARKET FOR HDA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 20 EUROPE: INAAT MARKET FOR HDA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 21 INAAT MARKET FOR NASBA, BY REGION, 2017–2024 (USD MILLION)
TABLE 22 NORTH AMERICA: INAAT MARKET FOR NASBA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 23 EUROPE: INAAT MARKET FOR NASBA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 24 INAAT MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 25 NORTH AMERICA: INAAT MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 26 EUROPE: INAAT MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 27 INAAT MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 28 INAAT MARKET FOR INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2017–2024 (USD MILLION)
TABLE 29 NORTH AMERICA: INAAT MARKET FOR INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 30 EUROPE: INAAT MARKET FOR INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 31 INAAT MARKET FOR INFECTIOUS DISEASE DIAGNOSIS, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 32 INAAT MARKET FOR HEPATITIS DIAGNOSIS, BY REGION, 2017–2024 (USD MILLION)
TABLE 33 NORTH AMERICA: INAAT MARKET FOR HEPATITIS DIAGNOSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 34 INAAT MARKET FOR CT/NG DIAGNOSIS, BY REGION, 2017–2024 (USD MILLION)
TABLE 35 NORTH AMERICA: INAAT MARKET FOR CT/NG DIAGNOSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 36 INAAT MARKET FOR HIV DIAGNOSIS, BY REGION, 2017–2024 (USD MILLION)
TABLE 37 NORTH AMERICA: INAAT MARKET FOR HIV DIAGNOSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 38 INAAT MARKET FOR INFLUENZA DIAGNOSIS, BY REGION, 2017–2024 (USD MILLION)
TABLE 39 NORTH AMERICA: INAAT MARKET FOR INFLUENZA DIAGNOSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 40 INAAT MARKET FOR OTHER INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2017–2024 (USD MILLION)
TABLE 41 NORTH AMERICA: INAAT MARKET FOR OTHER INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 42 INAAT MARKET FOR BLOOD SCREENING, BY REGION, 2017–2024 (USD MILLION)
TABLE 43 NORTH AMERICA: INAAT MARKET FOR BLOOD SCREENING, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 44 EUROPE: INAAT MARKET FOR BLOOD SCREENING, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 45 INAAT MARKET FOR OTHER APPLICATIONS, BY REGION, 2017–2024 (USD MILLION)
TABLE 46 NORTH AMERICA: INAAT MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 47 EUROPE: INAAT MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 48 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 49 INAAT MARKET FOR HOSPITALS, BY REGION, 2017–2024 (USD MILLION)
TABLE 50 NORTH AMERICA: INAAT MARKET FOR HOSPITALS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 51 EUROPE: INAAT MARKET FOR HOSPITALS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 52 INAAT MARKET FOR REFERENCE LABORATORIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 53 NORTH AMERICA: INAAT MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 54 EUROPE: INAAT MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 55 INAAT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2017–2024 (USD MILLION)
TABLE 56 NORTH AMERICA: INAAT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 57 EUROPE: INAAT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 58 INAAT MARKET FOR OTHER END USERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 59 NORTH AMERICA: INAAT MARKET FOR OTHER END USERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 60 EUROPE: INAAT MARKET FOR OTHER END USERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 61 INAAT MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 62 NORTH AMERICA: INAAT MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 63 NORTH AMERICA: INAAT MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 64 NORTH AMERICA: INAAT MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 65 NORTH AMERICA: INAAT MARKET FOR INFECTIOUS DISEASE DIAGNOSIS, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 66 NORTH AMERICA: INAAT MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 67 NORTH AMERICA: INAAT MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 68 US: INAAT MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 69 US: INAAT MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 70 US: INAAT MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 71 US: INAAT MARKET FOR INFECTIOUS DISEASE DIAGNOSIS, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 72 US: INAAT MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 73 CANADA: INAAT MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 74 CANADA: INAAT MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 75 CANADA: INAAT MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 76 CANADA: INAAT MARKET FOR INFECTIOUS DISEASE DIAGNOSIS, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 77 CANADA: INAAT MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 78 EUROPE: INAAT MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 79 EUROPE: INAAT MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 80 EUROPE: INAAT MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 81 EUROPE: INAAT MARKET FOR INFECTIOUS DISEASE DIAGNOSIS, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 82 EUROPE: INAAT MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 83 EUROPE: INAAT MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 84 GERMANY: INAAT MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 85 GERMANY: INAAT MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 86 GERMANY: INAAT MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 87 GERMANY: INAAT MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 88 FRANCE: INAAT MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 89 FRANCE: INAAT MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 90 FRANCE: INAAT MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 91 FRANCE: INAAT MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 92 UK: INAAT MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 93 UK: INAAT MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 94 UK: INAAT MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 95 UK: INAAT MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 96 ROE: INAAT MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 97 ROE: INAAT MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 98 ROE: INAAT MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 99 ROE: INAAT MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 100 APAC: INAAT MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 101 APAC: INAAT MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 102 APAC: INAAT MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 103 APAC: INAAT MARKET FOR INFECTIOUS DISEASE DIAGNOSIS, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 104 APAC: INAAT MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 105 ROW: INAAT MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 106 ROW: INAAT MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 107 ROW: INAAT MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 108 ROW: INAAT MARKET FOR INFECTIOUS DISEASE DIAGNOSIS, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 109 ROW: INAAT MARKET, BY END USER, 2017–2024 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARIES
FIGURE 3 MARKET SIZE ESTIMATION: INAAT MARKET
FIGURE 4 DATA TRIANGULATION METHODOLOGY
FIGURE 5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET SHARE, BY PRODUCT, 2018
FIGURE 6 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET SHARE, BY APPLICATION, 2018
FIGURE 7 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY TYPE, 2018
FIGURE 8 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET SHARE, BY END USER, 2018
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF THE ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET
FIGURE 10 RISING PREVALENCE OF INFECTIOUS DISEASES AND THE EMERGENCE OF NEWER PATHOGENS—KEY MARKET GROWTH DRIVERS
FIGURE 11 ASSAYS, KITS, & REAGENTS TO ACCOUNT FOR THE LARGEST SHARE OF
THE NORTH AMERICAN INAAT MARKET IN 2019
FIGURE 12 HOSPITALS TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2019
FIGURE 13 INFECTIOUS DISEASE DIAGNOSIS TO ACCOUNT FOR THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD
FIGURE 14 TRANSCRIPTION-MEDIATED AMPLIFICATION TECHNOLOGY TO ACCOUNT FOR
THE LARGEST SHARE OF THE MARKET IN 2019
FIGURE 15 INAAT MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 16 NORTH AMERICA: INAAT MARKET SNAPSHOT
FIGURE 17 APAC: INAAT MARKET SNAPSHOT
FIGURE 18 RANK OF COMPANIES IN THE ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, 2018
FIGURE 19 GLOBAL ISOTHERMAL NUCLEIC ACID TECHNOLOGY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2018
FIGURE 20 GRIFOLS: COMPANY SNAPSHOT (2018)
FIGURE 21 HOLOGIC, INC.: COMPANY SNAPSHOT (2018)
FIGURE 22 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2018)
FIGURE 23 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2018)
FIGURE 24 MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT (2018)
FIGURE 25 EIKEN CHEMICALS: COMPANY SNAPSHOT (2018)
FIGURE 26 QUIDEL CORPORATION: COMPANY SNAPSHOT (2018)
FIGURE 27 TECAN TRADING AG: COMPANY SNAPSHOT (2018)
FIGURE 28 DIASORIN: COMPANY SNAPSHOT (2018)
FIGURE 29 QIAGEN: COMPANY SNAPSHOT (2018)
FIGURE 30 ILLUMINA: COMPANY SNAPSHOT (2018)
FIGURE 31 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018)
FIGURE 32 BIOM?RIEUX SA: COMPANY SNAPSHOT (2018)
FIGURE 33 GE HEALTHCARE: COMPANY SNAPSHOT (2018)


More Publications